Registration - Amendment
KING & SPALDING LLP for AMARIN PHARMA, INC.
Firm
Client
Income
—
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Advocacy related to cardiovascular health and reduction of residual risk after statins.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SCOTT DZIENGELSKI New | Rep. Murphy (PA-18): Leg. Dir. (2015-2017), Sr. Leg. Asst. (2013-2015), Leg. Asst. (2012-2013), Leg. Corr. (2011-2012), Staff Asst. (2010-2011); Energy and Commerce Committee: Staff (2015-2017) |
| DAVID JOSEPH FARBER New | — |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| AMARIN CORPORATION PLC | Ireland | Ireland | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.